Effects of Lingguibafa-based Acupuncture on the Level of Blood Lactic Acid after Exhaustive Exercise

目的:观察灵龟八法针刺消除台阶运动疲劳后血乳酸的作用效果。方法:40名体育专业健康男性大学生随机分为灵龟八法照海开闭穴组(简称照海组)、灵龟八法申脉闭开穴组(简称申脉组)、辩证取穴组(简称三阴交组)和对照组4组,每组10人。实验分两个阶段:第一阶段选在照海穴开穴时间段进行。4组受试者进行台阶运动至疲劳后平卧,照海组、申脉组和三阴交组分别进行针刺,照海组选取双侧照海穴、列缺穴,申脉组选取双侧申脉穴、后溪穴,三阴交组选取双侧三阴交穴、合谷穴。留针30分钟,每10分钟行捻转补法1次。对照组平卧床上,不进行任何恢复干预。第二阶段:第一阶段实验结束24小时后,在申脉穴开穴时间段进行,方法同第一阶段。测定受试者两个阶段台阶运动前、运动停止30分钟后血乳酸值。结果:(1)第一阶段台阶运动停止30分钟后,照海组、申脉组和对照组的血乳酸值显著高于运动前(P0.05)。(2)第一阶段台阶运动24小时后,照海组和三阴交组血乳酸值显著低于运动前(P0.05);照海组和对照组之间比较有显著性差异(P0.05)。结论:灵龟八法针刺和辩证取穴针刺均有促进台阶运动后乳酸清除、降低血乳酸浓度的作用。Objective To observe the effects of Lingguibafa-based acupuncture blood lactic acid （BLA） after exhaustive step test. Methods 40 healthy male students were divided randomly and equally into 4 groups：group Zhaohai （ZH）,group Sh Sanyi-jiao（SYJ） and control group（C）. At first,all examinates began exhaustive step the opening of Zhaohai point according to Lingguibafa on elimination of majoring in sports enmai （SM）, group test precisely from ,then received acupuncture at Zhaohai and Lieque points for group ZH, Shenmai and Houxi points for group SM, and Sanyi-jiao and Hegu points for group SYJ. Needles were retained for 30 minutes. Examinat.es in group C received no acupuncture after exhaustive step test. 24 hours later,second exhaustive step test repeated again precisely from the opening of Shenmai point, and the acupuncture process was the same as the first test. BLA was measured before and 30 minutes after the step test. Results （1）BLAs after 30 minutes of the first step test were higher in groups ZH（P 〈 0.05） ,SM（P 〈 0.05） and C（P 〈 0.01） than that before the test（P 〈 0.05, P 〈 0.01 ）, except in group SYJ （P 〉 0.05 ）. （2）The B I_~s of groups ZH and SYJ were significantly lower than those before the second step test （P 〈 0.01 and P 〈 0.05 ,respectively） ,and BLAs of groups SM and C remained unchanged （P 〉 0.05）. There was significant difference in BLA between groups ZH and C after the second step test （P 〈 0.05）.（3）The BLAs of groups ZH,SM and C were significantly higher than that before the second step test（P 〈 0.01 ） ,except that of group SYJ（P 〉 0.05）. Conclusion Lingguibafa-based acupuncture can eliminate the accumulation of lactic acid after exhaustive exercise

新型电荷型纳米盘的可控制备及其与细胞色素p450的结合性能

分别采用氮气吹干法和旋转蒸发法制备由磷脂和膜支架蛋白组成的电荷型纳米盘,用凝胶过滤色谱对其尺寸分级,分析了其性能,考察了其与肝微粒体细胞色素P450的结合能力。结果表明,纳米盘外观澄清透明,微观呈圆盘状,平均直径10 nm,在pH 7.4下Zeta电位为-19.86 mV;肝微粒体破碎液与纳米盘能很好结合,CO差示光谱在450 nm出现明显吸收峰,细胞色素P450含量为0.10 nmol/mg,比活比未经纳米盘处理时提高13.0倍,较传统方法提升1.5倍,且操作时间由数日缩短至数小时。电荷型纳米盘在结合膜蛋白细胞色素P450的同时,活性保持良好,在膜蛋白研究领域极具应用潜力

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

Measurement of integrated luminosity of data collected at 3.773 GeV by BESIII from 2021 to 2024

We present a measurement of the integrated luminosity e+e- of collision data collected by the BESIII detector at the BEPCII collider at a center-of-mass energy of Ecm = 3.773 GeV. The integrated luminosities of the datasets taken from December 2021 to June 2022, from November 2022 to June 2023, and from October 2023 to February 2024 were determined to be 4.995±0.019 fb-1, 8.157±0.031 fb-1, and 4.191±0.016 fb-1, respectively, by analyzing large angle Bhabha scattering events. The uncertainties are dominated by systematic effects, and the statistical uncertainties are negligible. Our results provide essential input for future analyses and precision measurements

Determination of the number of ψ(3686) events taken at BESIII

The number of ψ(3686) events collected by the BESIII detector during the 2021 run period is determined to be (2259.3±11.1)×106 by counting inclusive ψ(3686) hadronic events. The uncertainty is systematic and the statistical uncertainty is negligible. Meanwhile, the numbers of ψ(3686) events collected during the 2009 and 2012 run periods are updated to be (107.7±0.6)×106 and (345.4±2.6)×106, respectively. Both numbers are consistent with the previous measurements within one standard deviation. The total number of ψ(3686) events in the three data samples is (2712.4±14.3)×10^